Buur T, Larsson R, Regårdh C G, Aberg J
Department of Nephrology, Linköping University Hospital, Sweden.
J Clin Pharmacol. 1991 Aug;31(8):709-13. doi: 10.1002/j.1552-4604.1991.tb03764.x.
Five chronic hemodialysis patients (1 woman and 4 men, aged, 46-68 yr) were given an oral dose of 10 mg felodipine followed by 0.057 mg [3H] felodipine IV. After 5 hours, a hemodialysis treatment lasting 4 hours was performed. Blood and dialysate flows were 200 mL/min and 500 mL/min, respectively. Capillary dialyzers with 1.3 m2 cellulose acetate membrane were used. The pharmacokinetic characteristics and reduction in diastolic BP were similar to those in hypertensive patients with normal renal function and in uremic patients who were not treated with dialysis. There was no measurable removal of felodipine by hemodialysis. Dialyzer clearance of radioactive metabolites was about 10 mL/min, and only 8.9% of the dose was eliminated by the treatment. The half-life of radioactive metabolites was 10 days (6-14 days) in three patients dialyzed thrice weekly. Since the metabolites are biologically inactive, no adjustment of dose is required in hemodialysis patients.
对5例慢性血液透析患者（1名女性和4名男性，年龄46 - 68岁）口服10 mg非洛地平，随后静脉注射0.057 mg [³H]非洛地平。5小时后，进行了一次持续4小时的血液透析治疗。血液和透析液流量分别为200 mL/分钟和500 mL/分钟。使用了具有1.3 m²醋酸纤维素膜的毛细管透析器。其药代动力学特征以及舒张压降低情况与肾功能正常的高血压患者和未接受透析治疗的尿毒症患者相似。血液透析未检测到非洛地平的清除。透析器对放射性代谢物的清除率约为10 mL/分钟，且该治疗仅消除了8.9%的剂量。在每周透析三次的3例患者中，放射性代谢物的半衰期为10天（6 - 14天）。由于这些代谢物无生物活性，血液透析患者无需调整剂量。
